<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287298</url>
  </required_header>
  <id_info>
    <org_study_id>14-07-0540</org_study_id>
    <nct_id>NCT02287298</nct_id>
  </id_info>
  <brief_title>Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment</brief_title>
  <official_title>Triple Combination Therapy of Choroidal Neovascularization in Exudative Age-related Macular Degeneration - a Cost Effect and Efficient Therapeutic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Retina Center of St. Louis County, PC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Retina Center of St. Louis County, PC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We propose to undertake a retrospective review of approximately 200 patients with a diagnosis
      of exudative macular degeneration treated with triple combination therapy (Bevacizumab,
      Dexamethasone and Photo-dynamic therapy) during the years of 2006 to 2010 at The Retina
      Center and compare those results with an additional group of approximately 200 patients also
      treated with triple combination therapy and 20 mg of daily oral zeaxanthin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study parameters will include best corrected visual acuity, number of combination treatments,
      reduction of central foveal thickness by OCT measurement and development of exudative macular
      degeneration in the fellow eye. Follow up will include all patients with a minimum of two
      years. Retrospective review of patient charts in the office of The Retina Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BEST CORRECTED VISUAL ACUITY</measure>
    <time_frame>REVIEW OF EXAMINATION SHEETS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NUMBER OF COMBINATION TREATMENTS</measure>
    <time_frame>REVIEW OF CHART</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>REDUCTION OF CENTRAL FOVEAL THICKNESS BY OCT MEASUREMENT</measure>
    <time_frame>REVIEW OF CHART</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DEVELOPMENT OF EXUDATIVE MACULAR DEGENERATION IN THE FELLOW EYE</measure>
    <time_frame>REVIEW OF CHART</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Exudative Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>2006 TO 2010 PATIENTS</arm_group_label>
    <description>PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CURRENT PATIENTS</arm_group_label>
    <description>PATIENTS TREATED WITH TRIPLE COMBINATION THERAPY AND ADDITION OF 20 MG OF ORAL ZEAXANTHIN</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TRIPLE COMBINATION THERAPY</intervention_name>
    <description>TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY</description>
    <arm_group_label>2006 TO 2010 PATIENTS</arm_group_label>
    <arm_group_label>CURRENT PATIENTS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PATIENTS MUST HAVE A DIAGNOSIS CODE OF AGE RELATED MACULAR DEGENERATION AND MUST BE 50
        YEARS OR OLDER AND HAVE EXUDATIVE AMD IN ATLEAST ONE EYE
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - MUST HAVE AGE RELATED MACULAR DEGENERATION

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ROBERT J OLK, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>THE RETINA CENTER</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Retina Center</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

